Alembic Pharmaceuticals receives USFDA approval for Binimetinib Tablets, 45 mg
The story in brief
Alembic Pharmaceuticals received USFDA approval for Binimetinib Tablets, 45 mg, following tentative approval for the 15 mg formulation. The approved ANDA is therapeutically equivalent to Mektovi Tablets, 15 mg of Array. Binimetinib, a kinase inhibitor, is indicated for unresectable or metastatic melanoma with BRAF V600E/V600K mutations, in combination with encorafenib, and for metastatic NSCLC with BRAF V600E mutations.